Adverum Biotechnologies Reports $47.7 Million Net Loss and Plans Merger with Eli Lilly

Adverum Biotechnologies, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $47.7 million for the quarter, compared to a loss of $32.4 million in the same period last year, marking an increase of 47%. For the nine months ended September 30, 2025, the net loss reached $143.9 million, up from $90.0 million in the prior year. The increase in losses is attributed primarily to heightened research and development expenses, which surged to $38.9 million for the quarter, up from $20.4 million a year earlier, driven largely by costs associated with the Phase 3 clinical development of its lead product candidate, Ixo-vec.

The company’s total operating expenses for the third quarter of 2025 were $48.0 million, a 35% increase from $35.4 million in the same quarter of 2024. This rise was primarily due to increased spending on clinical trials and personnel-related costs. Adverum did not generate any license revenue during the quarter, a stark contrast to the $1.0 million reported in the same period last year, which was linked to a milestone payment from a previous agreement. As of September 30, 2025, Adverum's accumulated deficit stood at $1.2 billion, reflecting ongoing financial strain.

In terms of strategic developments, Adverum is in the process of merging with Eli Lilly and Company, a move that is subject to various conditions. The merger agreement, signed on October 24, 2025, includes a tender offer for Adverum's shares at $3.56 each, along with contingent value rights that could yield additional payments based on future milestones related to Ixo-vec. The merger is expected to close in the fourth quarter of 2025, but the pending transaction has raised concerns about the company's ability to attract and retain talent and maintain relationships with stakeholders during this transitional period.

Operationally, Adverum has faced challenges, including a significant increase in current liabilities, which rose to $44.7 million from $22.9 million at the end of 2024. The company has also reported a material weakness in its internal controls over financial reporting, particularly concerning lease accounting, which has led to misstatements in prior financial statements. As of the latest filing, Adverum had cash and cash equivalents of $26.1 million, a sharp decline from $125.7 million at the end of 2024, raising substantial doubt about its ability to continue as a going concern without additional funding.

Looking ahead, Adverum anticipates continued losses as it progresses through clinical trials and seeks regulatory approvals for Ixo-vec. The company has indicated that it will require substantial additional funding to support its operations and product development efforts. If the merger with Eli Lilly does not proceed as planned, Adverum may face severe financial constraints, potentially leading to operational cutbacks or asset liquidation. The company’s future performance will largely depend on the successful completion of the merger and the advancement of its clinical programs.